USFDA clears Strides’ manufacturing unit in Bengaluru
USFDA clears Strides' manufacturing unit in Bengaluru The Bengaluru facility is Strides' flagship manufacturing site and caters to regulated and other international markets.
USFDA clears Strides' manufacturing unit in Bengaluru The Bengaluru facility is Strides' flagship manufacturing site and caters to regulated and other international markets.
Article outline
- What happened
- Why it matters
- The details
- The bottom line
Key points
- The USFDA conducted a current Good Manufacturing Practices (cGMP) inspection of the facility between May 12 and May 20, 2026.
- Strides Pharma Science Limited on Thursday remarked its flagship manufacturing facility in Bengaluru has received the Establishment Inspection Report (EIR) from the U.S.
- The Bengaluru facility is Strides' flagship manufacturing site and caters to regulated and other international markets.
- After assessing the company's response and the actions taken, the USFDA classified the inspection outcome as Voluntary Action Indicated (VAI) and issued the EIR, thereby concluding the inspection.
- Strides remarked it submitted a comprehensive response to the observations within the stipulated timeline and implemented corrective and preventive actions (CAPAs) to address the matters raised.
Strides Pharma Science Limited on Thursday remarked its flagship manufacturing facility in Bengaluru has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA), marking the successful closure of the regulatory inspection.
In practice, the USFDA conducted a current Good Manufacturing Practices (cGMP) inspection of the facility between May 12 and May 20, 2026. The inspection concluded with the issuance of a Form 483, containing five observations.
Meanwhile, the Bengaluru facility is Strides' flagship manufacturing site and caters to regulated and other international markets. It manufactures a broad set of pharmaceutical dosage forms, including tablets, capsules and oral liquids.
According to the firm, the facility supports both existing commercial products and future expansion opportunities throughout its international markets.
In short, USFDA clears Strides' manufacturing unit in Bengaluru is the central thread here, and readers can expect follow-up reporting as the picture becomes clearer.
